An Observational Study of Patients Living With Chronic Neurological Diseases
Launched by TARGET PHARMASOLUTIONS, INC. · Mar 21, 2023
Trial Information
Current as of July 23, 2025
Not yet recruiting
Keywords
ClinConnect Summary
The TARGET-NEURO study is a research project that aims to understand the experiences and outcomes of patients living with chronic neurological diseases, including Alzheimer's disease, mild cognitive impairment, Parkinson's disease, and multiple sclerosis. By gathering information from these patients, the study hopes to better understand how these conditions affect daily life and overall health.
To participate, individuals must be adults aged 60 and older with a diagnosis of one of the listed conditions. They will need to provide consent to take part in the study, and in some cases, their care partners may also be invited to participate in surveys. Participants can expect to share their experiences over a period of time, helping researchers gain valuable insights into living with these diseases. It’s important to note that the study is not yet recruiting participants, so interested individuals will need to wait for further announcements.
Gender
ALL
Eligibility criteria
- • Disease Cohort
- Inclusion Criteria:
- • •Adult patients at the time of enrollment with a diagnosis of ADRD, MCI, PD, or MS by select ICD-10 codes in the EHR interface
- Exclusion Criteria:
- • Death
- • Manual removal (sponsor or site request)
- • No EHR interface encounter \> 3 years
- • Engaged Cohort
- Inclusion Criteria:
- • Adult patients diagnosed and managed for these conditions invited to participate
- • Ability to provide written informed consent (or have a legally authorized representative to provide informed consent)
- • Care partners may be invited to participate in surveys and will provide informed consent.
- Exclusion Criteria:
- • Patient expressed desire to withdraw consent to complete PROs
- • Care partner expressed desire to withdraw consent to complete PROs
- • Failure to complete PROs within 24 weeks of initial invitation
- • Greater than 24 months lapse of survey completion after baseline surveys completed
- • Additionally, the criteria detailed for Disease Cohort apply to the Engaged Cohort
- • Age Cohort
- Inclusion Criteria:
- • •Adult patients aged 60 and older at time of enrollment
- Exclusion Criteria:
- • Death
- • Manual removal (sponsor or site request)
- • No EHR interface encounter \> 3 years
About Target Pharmasolutions, Inc.
Target Pharmasolutions, Inc. is a leading clinical trial sponsor dedicated to advancing pharmaceutical research and development. With a focus on innovative solutions, the company specializes in providing comprehensive clinical trial management services that enhance the efficiency and effectiveness of drug development. Target Pharmasolutions leverages cutting-edge technology and a team of experienced professionals to ensure regulatory compliance and optimize patient engagement, ultimately facilitating the successful delivery of new therapies to market. Committed to quality and integrity, the company partners with biopharmaceutical organizations to support their clinical goals and drive transformative outcomes in healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials